In collaboration with our member health services, global investigators, and through funding by the Victorian Department of Health and the MRFF (Australian Government Department of Health, Disability and Ageing), Regional Trials Network Victoria and the ReViTALISE project have enabled equitable access to high-quality clinical trials in regional Victoria.
As a result, we are seeing improved outcomes for regional patients living with cancer. Several recent studies have been published in the following journals, highlighting this changed paradigm:
1. Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Non-randomised Clinical Trial
Published 3 July 2025, JAMA Oncology
https://jamanetwork.com/journals/jamaoncology/article-abstract/2835771
2. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Published 17 June 2025, Springer Nature, Signal Transduction and Targeted Therapy 10:189 https://doi.org/10.1038/s41392-025-02274-z
3. Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Published 28 April 2025, Springer Nature, Investigational New Drugs; Vol.43, (pg435–445) https://link.springer.com/article/10.1007/s10637-025-01533-8
4. Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomised phase II trial
Published 25 March 2025, British Journal of Cancer, 132 (pg897–904)
https://www.nature.com/articles/s41416-025-02983-w
5. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomised DYNAMIC trial
Published 7 March 2025, Nature Medicine, Vol.31, (pg1509–1518) https://www.nature.com/articles/s41591-025-03579-w